Analysts Set Cabot Corporation (NYSE:CBT) Target Price at $80.25

Shares of Cabot Corporation (NYSE:CBT) have earned an average recommendation of “Hold” from the six brokerages that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $80.25.

CBT has been the subject of several research reports. JPMorgan Chase & Co. lifted their price target on shares of Cabot from $68.00 to $70.00 and gave the company an “underweight” rating in a report on Wednesday, May 13th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Cabot in a report on Tuesday, May 26th. UBS Group lifted their price target on shares of Cabot from $81.00 to $86.00 and gave the company a “neutral” rating in a report on Friday, May 8th. Wall Street Zen raised shares of Cabot from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Finally, Mizuho lifted their price target on shares of Cabot from $75.00 to $80.00 and gave the company a “neutral” rating in a report on Wednesday, May 6th.

Cabot Trading Down 2.1%

NYSE CBT opened at $85.45 on Friday. Cabot has a one year low of $58.33 and a one year high of $89.46. The company has a 50-day simple moving average of $78.69 and a 200-day simple moving average of $72.79. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.96 and a current ratio of 1.45. The firm has a market capitalization of $4.41 billion, a PE ratio of 16.15, a price-to-earnings-growth ratio of 11.52 and a beta of 0.82.

Cabot (NYSE:CBT) last posted its quarterly earnings results on Tuesday, May 5th. The specialty chemicals company reported $1.61 EPS for the quarter, beating the consensus estimate of $1.47 by $0.14. Cabot had a net margin of 7.97% and a return on equity of 21.33%. The business had revenue of $904.00 million during the quarter, compared to analyst estimates of $900.31 million. During the same period in the previous year, the business posted $1.90 EPS. The company’s quarterly revenue was down 3.4% on a year-over-year basis. Cabot has set its FY 2026 guidance at 6.000-6.50 EPS. On average, equities analysts forecast that Cabot will post 6.32 earnings per share for the current year.

Cabot Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 29th will be paid a dividend of $0.4725 per share. This represents a $1.89 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Friday, May 29th. This is a positive change from Cabot’s previous quarterly dividend of $0.45. Cabot’s dividend payout ratio (DPR) is presently 35.73%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CBT. NewEdge Advisors LLC boosted its stake in Cabot by 2,559.5% during the 1st quarter. NewEdge Advisors LLC now owns 984 shares of the specialty chemicals company’s stock valued at $82,000 after purchasing an additional 947 shares during the period. Goldman Sachs Group Inc. boosted its stake in Cabot by 32.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 442,646 shares of the specialty chemicals company’s stock valued at $36,802,000 after purchasing an additional 108,645 shares during the period. Empowered Funds LLC boosted its stake in Cabot by 102.6% during the 1st quarter. Empowered Funds LLC now owns 28,162 shares of the specialty chemicals company’s stock valued at $2,341,000 after purchasing an additional 14,260 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Cabot by 3.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 122,022 shares of the specialty chemicals company’s stock valued at $10,145,000 after purchasing an additional 4,048 shares during the period. Finally, Geneos Wealth Management Inc. boosted its stake in Cabot by 409.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 453 shares of the specialty chemicals company’s stock valued at $38,000 after purchasing an additional 364 shares during the period. 93.18% of the stock is owned by institutional investors and hedge funds.

Cabot Company Profile

Cabot Corporation is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. Founded in 1882 by Godfrey Lowell Cabot, the company has grown into a diversified manufacturer with operations across North America, Europe, Asia and Latin America. Cabot serves a wide range of end markets, including automotive, industrial, energy, and consumer products, supplying essential ingredients that enhance performance, durability and functionality.

The company operates two primary segments: Reinforcement Materials and Performance Materials.